🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to researchers.

An International Challenge

Gonorrhoea infections are on the rise around the world, with data suggesting more than 82 million new cases annually. Notably increased rates are observed in Africa and nations within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Across England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the face of growing infection rates, escalating drug resistance and the extremely scarce available drugs presently on offer.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program revealed that resistance to key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This approval represents a significant shift in the management of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Testing Data and Global Access

According to results released by a prominent scientific publication, the new drug cured the vast majority of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which uses two antibiotics. The trial involved over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have shared positive views. Having a easy-to-administer therapy such as this is described as a "revolutionary step" for managing the epidemic. This is considered vital to reduce the burden of the infection for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.